← Back to Patent Explorer
US4559343A Expired / Lapsed US ⏱️ 0.0 years remaining

Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents

Assignee: Alcon Research LLC
•
Filing: 1982-09-07
•
Granted: 1985-12-17
•
Expires: 2002-09-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Xanthine derivatives are described which decrease the stinging associated with the application of ophthalmic acidic anti-inflammatory agents.

Inventors

  • 👤 Wesley W. Han
  • 👤 Robert E. Roehrs

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 15:10
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61P; A61P27/00; A61P27/02; A61P29/00

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 106 words
An aqueous, nonirritating, nonsteroidal, ophthalmic composition for topical application to the eye comprising: a therapeutically effective amount of suprofen for topical treatment of inflammation of the eye, and pharmaceutically acceptable salts thereof; a xanthine derivative being present in an amount between the amount of derivative soluble in the water of said composition and 0.05% by weight/volume of said composition which is effective to reduce the discomfort associated with suprofen upon topical application of said composition, said xanthine derivative being selected from the group consisting of theophylline, caffeine, theobromine and mixtures thereof; an ophthalmic preservative; and a buffer, to provide an isotonic, aqueous, nonirritating nonsteroidal ophthalmic composition.
Claim 2
Dependent Claim 106 words
An aqueous, nonirritating, nonsteroidal, ophthalmic composition for topical application to the eye comprising: a therapeutically effective amount of suprofen for topical treatment of inflammation of the eye, and pharmaceutically acceptable salts thereof; a xanthine derivative being present in an amount between the amount of derivative soluble in the water of said composition and 0.05% by weight/volume of said composition which is effective to reduce the discomfort associated with suprofen upon topical application of said composition, said xanthine derivative being selected from the group consisting of theophylline, caffeine, theobromine and mixtures thereof; an ophthalmic preservative; and a buffer, to provide an isotonic, aqueous, nonirritating nonsteroidal ophthalmic composition.
Claim 3
Dependent Claim 17 words
An aqueous, nonirritating, nonsteroidal, ophthalmic composition as recited in claim 1 wherein said xanthine derivative is caffeine.
Claim 4
Dependent Claim 28 words
An aqueous, nonirritating, nonsteroidal ophthalmic composition as recited in claim 2 wherein said suprofen comprises between about 0.5 to about 3.0 percent by weight/volume of said ophthalmic composition.
Claim 5
Independent Claim 174 words
A method for reducing the stinging and discomfort associated with the topical application to the eye of an aqueous solution of a therapeutically effective amount of anti-inflammatory agent for topical treatment of inflammation of the eye, said agent selected from the group consisting of mefenamic acid, flufenamic acid, clonixin, flufenisal, 4-(t-butyl)benzeneacetic acid, ibufenac, ibuprofen, alclofenac, feneprofen, naproxen, indomethacin, tolmetin, flurbiprofen, ketoprofen, namoxyrate, suprofen, pharmaceutically acceptable salts of the foregoing acids and mixtures thereof, said method comprising adding to said aqueous solution an xanthine derivative in an amount between the amount of derivative soluble in the water of said composition and 0.05% by weight/volume of said composition which is effective to reduce the discomfort associated with said anti-inflammatory agent upon said topical application, said xanthine derivative having the formula ##STR2## where each of R 1 , R 2 and R 3 is selected from hydrogen, methyl and ethyl, and at least two of R 1 , R 2 and R 3 are selected from methyl and ethyl, and mixtures thereof forming a nonirritating ophthalmic composition.
Claim 6
Independent Claim 174 words
A method for reducing the stinging and discomfort associated with the topical application to the eye of an aqueous solution of a therapeutically effective amount of anti-inflammatory agent for topical treatment of inflammation of the eye, said agent selected from the group consisting of mefenamic acid, flufenamic acid, clonixin, flufenisal, 4-(t-butyl)benzeneacetic acid, ibufenac, ibuprofen, alclofenac, feneprofen, naproxen, indomethacin, tolmetin, flurbiprofen, ketoprofen, namoxyrate, suprofen, pharmaceutically acceptable salts of the foregoing acids and mixtures thereof, said method comprising adding to said aqueous solution an xanthine derivative in an amount between the amount of derivative soluble in the water of said composition and 0.05% by weight/volume of said composition which is effective to reduce the discomfort associated with said anti-inflammatory agent upon said topical application, said xanthine derivative having the formula ##STR2## where each of R 1 , R 2 and R 3 is selected from hydrogen, methyl and ethyl, and at least two of R 1 , R 2 and R 3 are selected from methyl and ethyl, and mixtures thereof forming a nonirritating ophthalmic composition.
Claim 7
Dependent Claim 24 words
A method as recited in claim 4 wherein said xanthine derivative is selected from the group consisting of theophylline, caffeine, theobromine and mixtures thereof.
Claim 8
Dependent Claim 19 words
A method as recited in claim 5 wherein said anti-inflammatory agent is suprofen and said xanthine derivative is caffeine.
Claim 9
Dependent Claim 24 words
A method as recited in claim 6 wherein said suprofen comprises between about 0.5 to about 3.0 percent by weight/volume of said ophthalmic composition.

References Cited (Backward Citations)

US2994640A Cited
US3439094A Cited
US3632742A Cited
US3957994A Cited
US4141976A Cited
JPS5697224A Cited
US4420483A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-12-16 1989-06-17 1989-12-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-12-16 1993-06-17 1993-12-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-12-16 1997-06-17 1997-12-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag